Results 91 to 100 of about 756 (101)

Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.

American Journal of Respiratory and Critical Care Medicine, 2018
Nicola LaVigne, Parameswaran Nair, Manali Mukherjee   +2 more
exaly  

Mepolizumab in eosinophilic disorders

Expert Review of Clinical Immunology, 2011
Philip E Putnam, J Pablo Abonia
exaly  

Mepolizumab—a novel option for the treatment of hypereosinophilic syndrome in childhood

Pediatric Allergy and Immunology, 2018
Susanne Lau, Ulrich Wahn, Carsten Schwarz   +2 more
exaly  

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma

Journal of Allergy and Clinical Immunology, 2017
Pranabashis Haldar, Hector Ortega, Ian D. Pavord   +2 more
exaly  

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma

Pediatric Pulmonology, 2019
Robert G Price, Atul Gupta, Jonathan Steinfeld   +2 more
exaly  

Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma

Respiratory Medicine, 2019
Namhee Kwon, Frank Albers, Santiago Quirce   +2 more
exaly  

Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study

Pulmonary Pharmacology and Therapeutics, 2018
Girolamo Pelaia, Corrado Pelaia, Maria Teresa Busceti   +2 more
exaly  

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment

Allergy: European Journal of Allergy and Clinical Immunology, 2016
exaly  

Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma

Allergy: European Journal of Allergy and Clinical Immunology
Peter G Gibson, Sarah A Hiles, Michael Fricker   +2 more
exaly  

Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients

Allergy: European Journal of Allergy and Clinical Immunology
John W Upham, Mark Hew, Sandra Hodge
exaly